JPMA Members’ Domestic Slump Compensated For By Overseas Growth
This article was originally published in PharmAsia News
Executive Summary
Drug price revisions and patent expirations for flagship drugs caused domestic sales slumps for the 27 members of the Japan Pharmaceutical Manufacturers Association listed on the Tokyo Stock Exchange, but overseas growth increased overall total sales by 2.1% to ¥4.37 trillion, according to JPMA’s overview of interim results for FY2013.